Smoking Cessation
Conditions
Keywords
Smoking cessation, Vernonia Cinerea, Non-communicable disease
Brief summary
Vernonia cinerea is an herbal which has been recorded in many Thai herbal formulation and Thai traditional medicine has used this herbal for treating various diseases included hypertension, asthma, fever, hepatitis, kidney stone and smoking cessation. Now aday there are more interest for using Vernonia cinerea as a medication to aid smoker to quit smoking because it is cheaper than other current therapeutic medications. The objective of this study is to evaluate efficacy and safety of Vernonia cinerea lozenge for smoking cessation when compared to placebo.
Detailed description
This study is a multicenter randomized, paralleled, double blind, controlled trial. This study will include 260 patients from Lerdsin hospital, Chest institute, Phramongkutklao hospital, Maharaj Nakorn Chiang Mai Hospital and Paolo Memorial Phaholyothin hospital who would like to quit smoke. Patients will be assigned into two groups, Vernonia cinerea group (n=130) and placebo group (n=130), both groups will be instructed to take one lozenge three times a day for three months. The two groups will receive individual counseling about smoking cessation technique by trained healthcare professional on every visit. The main primary outcome for this study is continuous abstinence rate (CAR), define as self-report of no cigarette smoking, not even a puff since target quit date, plus passed biochemical validation for 1 month.
Interventions
DIETARY_SUPPLEMENTVernonia cinerea
Vernonia cinerea is an herb that is claimed in many Thai medicinal formulas. In traditional medicines, they use this herbal to treat diseases such as hypertension, asthma, fever, hepatitis, gallstones, including use to help smoker quit smoking.
DIETARY_SUPPLEMENTPlacebo
Sweetener
Sponsors
Chulalongkorn University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
This study was a multicenter randomized, paralleled, double-blind, controlled trial at 5 hospitals and 2 community pharmacies in Thailand
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age at least 18 years old * Have at least 1 underlying non-communicable disease include hypertension, diabetes, dyslipidemia, cardiovascular diseases, cerebrovascular diseases, stable asthma (defined as no asthmatic exacerbation for the preceding 4 weeks necessitating oral prednisolone or an increased use of inhaled corticosteroid, the use of rescue treatment no more than three times a week, and with no clinical indication for change in treatment medication) COPD stage A-C according to GOLD guideline, chronic kidney diseases * Smoke 10 cigarettes or over per day at least 1 month prior to study * Desired to quit smoking * Consent to participate in study
Exclusion criteria
* Renal dysfunction (GFR \< 30 ml/mins/1.73m2) * Liver dysfunction (Child-Pugh score C) * Hyperkalemia (serum potassium ≥ 5 mEq/L) * Documented of active depression or psychosis * Active cancer * History of acute coronary syndrome in previous 4 weeks * Known case of pregnancy or lactation * Use other tobacco products or other addictive substances except alcohol * Use other smoking cessation drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| continuous abstinence rate | 1 month | self-report of no cigarette smoking, not even a puff since target quit date, plus passed biochemical validation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| continuous abstinence rate (CAR) and point prevalence rate | 3,6 and 12 months | self-report of no cigarette smoking, not even a puff since target quit date, plus passed biochemical validation |
Countries
Thailand
Outcome results
None listed